| Excerpt | Reference | Relevance |
|---|
| "Statistical analysis indicated a strong pharmacodynamic correlation between plasma drug concentrations at 1 h after dosing and the reduction in the severity of depression as measured by the psychiatric rating scales." | ( A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.
Abajian, H; Ehrensing, RH; Feighner, JP; Hlavka, J; Kastin, AJ; Leonard, BE; Nicolau, G; Noble, JF; Patel, A; Sverdlov, L, 2000) | 0.31 |
| "This was a pilot study conducted in a relatively small population (52 patients) and the limited number of blood sampling times did not allow a comprehensive pharmacokinetic analysis." | ( A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.
Abajian, H; Ehrensing, RH; Feighner, JP; Hlavka, J; Kastin, AJ; Leonard, BE; Nicolau, G; Noble, JF; Patel, A; Sverdlov, L, 2000) | 0.31 |
| " The purpose of our phase 1 clinical trials (conducted over a three year period) was to provide safety and pharmacokinetic data to support its clinical development as an antidepressant drug." | ( Clinical pharmacokinetic studies with INN 00835 (nemifitide), a novel pentapeptide antidepressant.
Abajian, H; Di Spirito, C; Faria, G; Feighner, JP; Hlavka, J; Marricco, NC; Morrison, J; Nicolau, G; Sverdlov, L; Tonelli, G, 2002) | 0.31 |
| Excerpt | Relevance | Reference |
|---|
| "Statistical analysis indicated a strong pharmacodynamic correlation between plasma drug concentrations at 1 h after dosing and the reduction in the severity of depression as measured by the psychiatric rating scales." | ( A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression.
Abajian, H; Ehrensing, RH; Feighner, JP; Hlavka, J; Kastin, AJ; Leonard, BE; Nicolau, G; Noble, JF; Patel, A; Sverdlov, L, 2000) | 0.31 |
| " Of the 55 enrolled patients, 22 were dosed for 10 days with drug, 11 for 5 days with drug followed by 5 days with placebo and 22 for 10 days with placebo only." | ( Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression.
Abajian, HB; Ehrensing, RH; Feighner, JP; Hlavka, J; Kastin, AJ; Nicolau, G; Noble, JF; Patel, A; Sverdlov, L, 2001) | 0.31 |
| " No serious adverse events or clinically significant systemic adverse events occurred at any of the doses investigated in the over 100 subjects dosed in these studies." | ( Clinical pharmacokinetic studies with INN 00835 (nemifitide), a novel pentapeptide antidepressant.
Abajian, H; Di Spirito, C; Faria, G; Feighner, JP; Hlavka, J; Marricco, NC; Morrison, J; Nicolau, G; Sverdlov, L; Tonelli, G, 2002) | 0.31 |
| " This small-scale, randomized, single-dose, parallel design, open-label pilot study consisted of three treatment groups of four subjects each dosed as follows: group 1: 40 mg of nemifitide administered by standard needle/syringe and groups 2 and 3: 40 and 80 mg nemifitide, respectively, administered by using a needle-free (Bioject injection delivery system." | ( Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers.
Ciric, S; Feighner, JP; Freed, J; Gutierrez, M; Hlavka, J; Nicolau, G; Stout, R, 2005) | 0.33 |